Roger E McLendon

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Glioblastoma Stem Cells: A Neuropathologist's View
    Roger E McLendon
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    J Oncol 2011:397195. 2011
  2. ncbi request reprint Errors in surgical neuropathology and the influence of cognitive biases: the psychology of intelligence analysis
    Roger E McLendon
    Division of Neuropathology, Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Arch Pathol Lab Med 130:613-6. 2006
  3. pmc Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects
    Roger E McLendon
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Nucl Med Biol 34:405-13. 2007
  4. pmc Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6
    Michael R Zalutsky
    Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Nucl Med 49:30-8. 2008
  5. pmc Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
    John H Sampson
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 28:4722-9. 2010
  6. pmc Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy
    Jennifer A Quinn
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 95:393-400. 2009
  7. pmc Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells
    Zhizhong Li
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Cell 15:501-13. 2009
  8. pmc A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:182-9. 2008
  9. pmc Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 115:2964-70. 2009
  10. pmc Targeting cancer stem cells through L1CAM suppresses glioma growth
    Shideng Bao
    Department of Surgery, Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 68:6043-8. 2008

Detail Information

Publications100

  1. pmc Glioblastoma Stem Cells: A Neuropathologist's View
    Roger E McLendon
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    J Oncol 2011:397195. 2011
    ..In this way we will come to better appreciate the impact our therapeutic interventions have on the regional phenotypic heterogeneity that exists within the tumor and the intercellular communications directing adaptation and progression...
  2. ncbi request reprint Errors in surgical neuropathology and the influence of cognitive biases: the psychology of intelligence analysis
    Roger E McLendon
    Division of Neuropathology, Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Arch Pathol Lab Med 130:613-6. 2006
    ..A significant difficulty that pathologists encounter in arriving at a correct diagnosis is related to the way information from various sources is processed and assimilated in context...
  3. pmc Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects
    Roger E McLendon
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Nucl Med Biol 34:405-13. 2007
    ....
  4. pmc Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6
    Michael R Zalutsky
    Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Nucl Med 49:30-8. 2008
    ..The main goal of this study was to investigate the feasibility and safety of this approach in patients with recurrent malignant brain tumors...
  5. pmc Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma
    John H Sampson
    Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 28:4722-9. 2010
    ..Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms...
  6. pmc Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy
    Jennifer A Quinn
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 95:393-400. 2009
    ..The lack of correlation of activity with MGMT expression is intriguing, but needs further evaluation in subsequent trials...
  7. pmc Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells
    Zhizhong Li
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Cell 15:501-13. 2009
    ..Our results demonstrate that GSCs differentially respond to hypoxia with distinct HIF induction patterns, and HIF2alpha might represent a promising target for antiglioblastoma therapies...
  8. pmc A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:182-9. 2008
    ..S. Food and Drug Administration has approved a trial randomizing newly diagnosed GBM patients to either our study regimen or standard XRT plus temozolomide...
  9. pmc Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 115:2964-70. 2009
    ..The trial was designed to determine the maximum tolerated dose (MTD) and toxicity of irinotecan (CPT-11) when administered with temozolomide (TMZ) and O(6)-benzylguanine (O(6)-BG)...
  10. pmc Targeting cancer stem cells through L1CAM suppresses glioma growth
    Shideng Bao
    Department of Surgery, Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 68:6043-8. 2008
    ....
  11. ncbi request reprint Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results
    David A Reardon
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC, 27710, USA
    J Clin Oncol 24:115-22. 2006
    ..To assess the efficacy and toxicity of intraresection cavity iodine-131-labeled murine antitenascin monoclonal antibody 81C6 (131I-m81C6) among recurrent malignant brain tumor patients...
  12. ncbi request reprint Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
    J Nucl Med 47:912-8. 2006
    ....
  13. pmc Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan
    Sith Sathornsumetee
    Department of Medicine, Duke University Medical Center, DUMC 2900, Durham, NC 27710, USA
    J Clin Oncol 26:271-8. 2008
    ....
  14. pmc c-Myc is required for maintenance of glioma cancer stem cells
    Jialiang Wang
    Department of Surgery, Duke University, Durham, North Carolina, USA
    PLoS ONE 3:e3769. 2008
    ..As the c-Myc oncoprotein has recognized roles in normal stem cell biology, we hypothesized that c-Myc may contribute to cancer stem cell biology as these cells share characteristics with normal stem cells...
  15. pmc Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma
    Tracy Ann Read
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Cell 15:135-47. 2009
    ..CD15 is also found in a subset of human medulloblastomas, and tumors expressing genes similar to those found in murine CD15(+) cells have a poorer prognosis. Thus, CD15 may represent an important marker for TPCs in medulloblastoma...
  16. pmc Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma
    Jennifer A Quinn
    Departments of Surgery, Duke University Medical Center, PO Box 3624, Durham, NC 27710, USA
    J Clin Oncol 27:1262-7. 2009
    ....
  17. pmc Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
    Jennifer A Quinn
    Dept of Medicine, Division of Neurology, Duke University Medical Center, Durham, NC, USA
    Neuro Oncol 11:556-61. 2009
    ..This study provides the foundation for a phase II trial of O(6)-BG in combination with a 5-day dosing schedule of TMZ in TMZ-resistant MG...
  18. pmc Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy
    Vidyalakshmi Chandramohan
    Preston Robert Tisch Brain Tumor Center at Duke and Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 19:4717-27. 2013
    ....
  19. pmc Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Box 3050, Room 220 Sands Building, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:320-9. 2008
    ..However, the potential efficacy of drugs delivered by this technique may be severely constrained by ineffective infusion in many patients...
  20. pmc Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Neuro Oncol 13:324-33. 2011
    ..EGFRvIII-targeted vaccination induces patient immune responses despite therapeutic TMZ-induced lymphopenia and eliminates EGFRvIII-expressing tumor cells without autoimmunity...
  21. pmc Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma
    David A Reardon
    Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 106:409-15. 2012
    ..The only grade 3 or greater adverse event occurring in ≥ 10% of patients was anemia (10%). Imatinib plus hydroxyurea is well tolerated among patients with meningioma but has modest anti-tumor activity for this indication...
  22. pmc Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme
    Jennifer A Quinn
    Department of Surgery, Pathology, Biostatistics, and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 15:1064-8. 2009
    ....
  23. pmc Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 107:155-64. 2012
    ..ClinicalTrials.gov number NCT00953121)...
  24. ncbi request reprint Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas
    Annick Desjardins
    Department of Medicine, Division of Neurology, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    J Neurooncol 83:53-60. 2007
    ..We performed the current phase 2 study to evaluate this regimen among patients with recurrent WHO grade III malignant glioma (MG)...
  25. pmc Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 96:219-30. 2010
    ..029). Erlotinib plus sirolimus was well tolerated but had negligible activity among unselected recurrent GBM patients. (ClinicalTrials.gov number: NCT0062243)...
  26. pmc Brain cancer stem cells display preferential sensitivity to Akt inhibition
    Christine E Eyler
    School of Medicine, Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham North Carolina, USA
    Stem Cells 26:3027-36. 2008
    ..Together, these results suggest that Akt inhibitors may function as effective anticancer stem cell therapies...
  27. pmc Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth
    Hui Wang
    Department of Pharmacology, Duke University Medical Center, Durham, North Carolina, USA
    Stem Cells 27:2393-404. 2009
    ..Together, our data indicate that IL6 signaling contributes to glioma malignancy through the promotion of GSC growth and survival, and that targeting IL6 may offer benefit for glioma patients...
  28. pmc OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas
    David C Adamson
    Department of Surgery, The Pediatric Brain Tumor Foundation Institute, and The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Veterans Affairs Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 70:181-91. 2010
    ..Mechanistic investigations revealed upregulation of MYC as a potential mechanism whereby OTX2 promotes tumor progression. Our findings define OTX2 as an important oncogenic driver in medulloblastoma...
  29. pmc Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
    Sith Sathornsumetee
    The Preston Robert Tisch Brain Tumor Center, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 12:1300-10. 2010
    ..Bevacizumab plus erlotinib was adequately tolerated in recurrent MG patients. However, this regimen was associated with similar PFS benefit and radiographic response when compared with other historical bevacizumab-containing regimens...
  30. ncbi request reprint Survival analysis of presumptive prognostic markers among oligodendrogliomas
    Roger E McLendon
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 104:1693-9. 2005
    ..However, the authors questioned the relevance of genetic testing and measuring MGMT levels in tumors that were diagnostic of oligodendroglioma...
  31. pmc Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab
    Abraham Boskovitz
    Department of Pathology, Duke University Medical Center, Durham, NC 27710 USA
    Nucl Med Biol 36:659-69. 2009
    ..The goal of this study was to evaluate the therapeutic effect of alpha-particle emitting (211)At-labeled trastuzumab following intrathecal administration in a rat model of breast carcinoma CM...
  32. pmc Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 117:5351-8. 2011
    ..The efficacy of carboplatin, irinotecan, and bevacizumab among recurrent glioblastoma (GBM) patients after prior progression on bevacizumab therapy in a phase 2, open-label, single-arm trial was evaluated...
  33. ncbi request reprint AAL881, a novel small molecule inhibitor of RAF and vascular endothelial growth factor receptor activities, blocks the growth of malignant glioma
    Sith Sathornsumetee
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Res 66:8722-30. 2006
    ....
  34. pmc A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastoma
    John H Sampson
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, United States of America
    PLoS ONE 7:e31046. 2012
    ..However, therapeutic approaches are complicated by the inadvertent inhibition of IL-2Rα expressing anti-tumor effector T-cells...
  35. pmc Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptors
    Michael R Zalutsky
    Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA
    Nucl Med Biol 39:23-34. 2012
    ..This motivated the generation of MAb D2C7, which recognizes both wild-type epidermal growth factor receptor (EGFRwt) and a tumor-specific mutant, EGFRvIII...
  36. pmc Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study
    John H Sampson
    Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 7:90-6. 2005
    ..This report describes a dramatic and sustained clinical and radiographic response in a patient with a bifrontal glioblastoma multiforme treated with intratumoral infusion of a novel targeted toxin, TP-38...
  37. pmc Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans
    Duane A Mitchell
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA
    Blood 118:3003-12. 2011
    ....
  38. pmc Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma
    Sridharan Gururangan
    Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 10:745-51. 2008
    ..The favorable impact of HDC on disease control in the two long-term survivors cannot be clearly established due to the cofounding effect of definitive RT postrecurrence...
  39. pmc Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma
    Jill A Maxwell
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 14:4859-68. 2008
    ..The purpose of this study was to determine the role of MMR deficiency in mediating resistance in samples from patients with both newly diagnosed malignant gliomas and those who have failed temozolomide therapy...
  40. ncbi request reprint Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
    Shideng Bao
    Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Nature 444:756-60. 2006
    ..Targeting DNA damage checkpoint response in cancer stem cells may overcome this radioresistance and provide a therapeutic model for malignant brain cancers...
  41. pmc Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC, 27710, USA
    J Neurooncol 101:57-66. 2011
    ..In conclusion, sorafenib can be safely administered with daily temozolomide, but this regimen has limited activity for recurrent GBM. Co-administration of EIAEDs can lower sorafenib exposures in this population...
  42. ncbi request reprint ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors
    Jeremy N Rich
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 11:8145-57. 2005
    ..Current nonspecific therapies frequently have poor efficacy in many of these tumor types, so there is a pressing need for the development of novel targeted therapies...
  43. ncbi request reprint Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study
    Gamal Akabani
    Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA
    J Nucl Med 46:1042-51. 2005
    ....
  44. ncbi request reprint Phase II trial of temozolomide in patients with progressive low-grade glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 21:646-51. 2003
    ..We have extended these results, and now we report results of a phase II trial of Temodar for patients with progressive, low-grade glioma...
  45. pmc MRP3: a molecular target for human glioblastoma multiforme immunotherapy
    Chien Tsun Kuan
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    BMC Cancer 10:468. 2010
    ..We have identified and validated a promising molecular therapeutic target that is expressed by GBM: human multidrug-resistance protein 3 (MRP3)...
  46. pmc A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma
    David A Reardon
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
    J Natl Compr Canc Netw 9:414-27. 2011
    ..Better understanding of resistance mechanisms to VEGF inhibitors and identification of effective therapy after bevacizumab progression are currently a critical need for patients with glioblastoma...
  47. ncbi request reprint Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer
    Peter M Grossi
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 9:5514-20. 2003
    ..Direct intracerebral microinfusion (ICM) is a technique that bypasses this blood-brain barrier and allows for a greater delivery of drugs directly into intracerebral tumors...
  48. pmc Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas
    Genglin Jin
    The Preston Robert Tisch Brain Tumor Center, The Pediatric Brain Tumor Foundation Institute, and the Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 73:496-501. 2013
    ..Expression of wild-type IDH1 was also critical for mutant IDH1-associated D-2HG production in the colorectal cancer cell line HCT116. These insights may aid in the development of therapeutic strategies to target IDH1-mutated cancers...
  49. pmc Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series
    Emil Lou
    Department of Surgery, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC, 27710, USA
    J Neurooncol 109:63-70. 2012
    ..Phase II trials investigating bevacizumab in patients with progressive/recurrent meningioma are warranted...
  50. ncbi request reprint Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid
    Chunhui Di
    Brain Tumor Center, Department of Pathology, Duke University Medical Center, Research Drive, Durham, NC 27710, USA
    Cancer Res 65:919-24. 2005
    ..These observations suggest that OTX2 is essential for the pathogenesis of anaplastic medulloblastomas and that these tumors may be amenable to therapy with all-trans-retinoic acid...
  51. ncbi request reprint Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC, USA
    J Clin Oncol 23:7178-87. 2005
    ..In addition, plasma concentrations of O6-BG and O6-benzyl-8-oxoguanine were evaluated after O6-BG...
  52. ncbi request reprint Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor
    Shideng Bao
    Department of Surgery, Preston Robert Tisch Brain Tumor Center, Molecular Cancer Biology Program, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Res 66:7843-8. 2006
    ..Together these data indicate that stem cell-like tumor cells can be a crucial source of key angiogenic factors in cancers and that targeting proangiogenic factors from stem cell-like tumor populations may be critical for patient therapy...
  53. pmc EGFRvIII-targeted vaccination therapy of malignant glioma
    Bryan D Choi
    Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Brain Pathol 19:713-23. 2009
    ..Additionally, the corresponding therapeutic outcomes observed in these studies lend credence to the potential role of peptide-based vaccination strategies among emerging antitumor immunotherapies in patients with malignant glioma...
  54. pmc Glioblastoma proto-oncogene SEC61gamma is required for tumor cell survival and response to endoplasmic reticulum stress
    Zheming Lu
    Department of Pathology, The Pediatric Brain Tumor Foundation Institute, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 69:9105-11. 2009
    ....
  55. pmc Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas
    Chien Tsun Kuan
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Cancer 127:598-611. 2010
    ..These Fv-based recombinant antibodies, which possess superior tumor penetration capabilities and selectively target tumor cells that express MRP3, may potentially be used in immunotherapy and diagnosis for brain tumors and other cancers...
  56. doi request reprint Utility of EGFR and PTEN numerical aberrations in the evaluation of diffusely infiltrating astrocytomas. Laboratory investigation
    Ryan T Mott
    Department of Pathology, Wake Forest University School of Medicine, Winston Salem, NC, USA
    J Neurosurg 108:330-5. 2008
    ..Given the important roles for EGFR and PTEN in the malignant progression of astrocytomas, the authors hypothesized that the fraction of tumor cells with aberrations in these genetic loci would correlate with the histological grade...
  57. ncbi request reprint Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin
    Hidenobu Ochiai
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
    Neurol Med Chir (Tokyo) 46:485-9; discussion 489-90. 2006
    ..005). These results suggest that intrathecal treatment with 9NC may be useful for patients with GBM neoplastic meningitis...
  58. ncbi request reprint Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas
    David A Reardon
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 20:1389-97. 2002
    ..To assess the efficacy and toxicity of intraresection cavity (131)I-labeled murine antitenascin monoclonal antibody 81C6 and determine its true response rate among patients with newly diagnosed malignant glioma...
  59. ncbi request reprint Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa)
    Amy B Heimberger
    Department of Surgery, Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 8:3496-502. 2002
    ..On the basis of these observations, we believe that clinical trials of ZD1839 against brain tumors expressing EGFR are warranted, but that special consideration should be given to tumors that coexpress EGFRvIII...
  60. pmc Detection of amino-terminal extracellular domain of somatostatin receptor 2 by specific monoclonal antibodies and quantification of receptor density in medulloblastoma
    Chien Tsun Kuan
    Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA
    Hybridoma (Larchmt) 28:389-403. 2009
    ..9 x 10(4) for the "glial" phenotype DAOY MED cell line and 0.6-8.8 x 10(5) for four neuronal phenotype MED cell lines. Our results indicate a potential immunotherapeutic application for these MAbs...
  61. ncbi request reprint Phase II trial of gefitinib in recurrent glioblastoma
    Jeremy N Rich
    Duke University Medical Center, Box 2900, Durham, NC 27710, USA
    J Clin Oncol 22:133-42. 2004
    ..To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma...
  62. ncbi request reprint Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant b
    John H Sampson
    Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
    J Neurooncol 65:27-35. 2003
    ..9 weeks. Overall, 3 of 15 patients, with residual disease at the time of therapy, have demonstrated radiographic responses and one patient with a complete response and has survived greater than 83 weeks...
  63. pmc Multiple phenotypic changes in mice after knockout of the B3gnt5 gene, encoding Lc3 synthase--a key enzyme in lacto-neolacto ganglioside synthesis
    Chien Tsun Kuan
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    BMC Dev Biol 10:114. 2010
    ....
  64. doi request reprint Clinicopathological characteristics and treatment of rhabdoid glioblastoma
    Ranjith Babu
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC, USA
    J Neurosurg 119:412-9. 2013
    ..The authors also review the literature to provide the most comprehensive understanding of these rare tumors to date...
  65. pmc A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation
    Yukinari Kato
    Department of Pathology, Duke University Medical Center, DUMC 3156, Durham, NC 27710, USA
    Biochem Biophys Res Commun 390:547-51. 2009
    ..In conclusion, we established an anti-IDH1(R132H)-specific monoclonal antibody IMab-1, which should be significantly useful for diagnosis and biological evaluation of mutation-bearing gliomas...
  66. pmc Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications
    Rodney N Wiltshire
    Duke University Medical Center, Department of Pathology, Box 3712, Durham, NC 27710, USA
    J Mol Diagn 6:166-79. 2004
    ..The cumulative effect of these loci is an important consideration in their diagnostic and prognostic implications...
  67. ncbi request reprint Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma
    Jill A Maxwell
    Department of Surgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
    Mol Cancer Ther 5:2531-9. 2006
    ..The data also suggest that consideration be given to the large population of AGT-expressing cells within samples when therapeutic strategies based on tumor methylation are used...
  68. ncbi request reprint Gene expression profiling and genetic markers in glioblastoma survival
    Jeremy N Rich
    Department of Medicine, W M Keck Center for Neuro Oncogenomics, Institute of Statistics and Decision Sciences, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Res 65:4051-8. 2005
    ....
  69. ncbi request reprint Molecular markers of prognosis in astrocytic tumors
    Ahmed Rasheed
    Department of Pathology, Duke University Medical Center, 3156, Durham, NC 27710, USA
    Cancer 94:2688-97. 2002
    ..To date, only age and histologic grade stand out as independent predictors of survival. There is now increased interest in the use of molecular markers as objective standards against which to establish diagnosis and grade...
  70. ncbi request reprint MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group
    Naji Aldosari
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Arch Pathol Lab Med 126:540-4. 2002
    ..Data on these tumors indicate that the frequency of MYCC amplification is 5% to 10%. Fluorescence in situ hybridization is a powerful tool for investigating these features on archival material...
  71. pmc Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience
    Christopher D Turner
    The Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 4:102-8. 2002
    ..Ongoing studies will demonstrate if activity of CPT-11 can be enhanced when combined with alkylating agents, including carmustine and temozolomide...
  72. doi request reprint Single-stage bilateral choroid plexectomy for choroid plexus papilloma in a patient presenting with high cerebrospinal fluid output
    Shahid M Nimjee
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Neurosurg Pediatr 5:342-5. 2010
    ..It can result in high CSF output and can be successfully treated with a single-stage bilateral choroid plexectomy. Further studies are ongoing to identify genes involved in embryogenesis of the choroid plexus...
  73. doi request reprint Bevacizumab fails to treat temporal paraganglioma: discussion and case illustration
    Hamidreza Aliabadi
    Department of Surgery, Division of Neurosurgery, Duke University Medical Center, 220 Sands Building, Research Drive, Box 3050, Durham, NC 27710, USA
    J Neurooncol 98:427-30. 2010
    ..This patient was treated with bevacizumab prior to surgical treatment; radiographic imaging at 3 months, however, showed no significant response. We discuss possible reasons for treatment failure...
  74. ncbi request reprint Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma
    Jennifer A Quinn
    Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 20:2277-83. 2002
    ....
  75. ncbi request reprint Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas
    Daniel K Broderick
    Brain Tumor Center, Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Cancer Res 64:5048-50. 2004
    ..These observations implicate PIK3CA as an oncogene in a wider spectrum of adult and pediatric brain tumors and suggest that PIK3CA may be a useful diagnostic marker or a therapeutic target in these cancers...
  76. ncbi request reprint Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition
    Ranjit K Goudar
    Department of Pathology, Duke University Medical Center, P O Box 2900, Durham, NC 27710, USA
    Mol Cancer Ther 4:101-12. 2005
    ..These studies suggest that simultaneous inhibition of growth factor receptor and mTOR pathways offer increased benefit in glioma therapy...
  77. ncbi request reprint Glioneuronal tumors of the central nervous system
    Roger E McLendon
    Department of Pathology, Duke University Medical Center 3712, Davison Building, Room M216, Durham, NC 27710, USA
    Brain Tumor Pathol 19:51-8. 2002
    ..For pathologists confronted by this growing array of tumors and subtypes, it is appropriate to focus on them and understand the differential diagnosis to be considered when confronted by them...
  78. doi request reprint Splenda alters gut microflora and increases intestinal p-glycoprotein and cytochrome p-450 in male rats
    Mohamed B Abou-Donia
    Department of Pharmacology, Duke University Medical Center, Durham, North Carolina 27708, USA
    J Toxicol Environ Health A 71:1415-29. 2008
    ....
  79. ncbi request reprint High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas
    Sridharan Gururangan
    Brain Tumor Center at Duke and the Department of Pediatrics, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 21:2187-91. 2003
    ..We evaluated the usefulness of a treatment regimen that included high-dose chemotherapy (HDC) with autologous stem-cell rescue (ASCR) in patients with newly diagnosed pineoblastoma (PBL)...
  80. ncbi request reprint Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: theoretical analysis
    Gamal Akabani
    Department of Radiology, Duke University Medical Center, Box 3808, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 54:1259-75. 2002
    ..To establish the theoretical framework and study the feasibility of (211)At-labeled anti-tenascin chimeric 81C6 monoclonal antibody (mAb) as anti-vascular endoradiotherapy for the treatment of glioblastoma multiforme (GBM) tumors...
  81. pmc Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma
    Duane A Mitchell
    Duke University Medical Center, Division of Neurosurgery, Department of Surgery, Durham, NC 27710, USA
    Neuro Oncol 10:10-8. 2008
    ....
  82. pmc IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain
    Giselle Y Lopez
    The Preston Robert Tisch Brain Tumor Center, The Pediatric Brain Tumor Foundation, and the Department of Pathology, Duke University Medical Center, DUMC 3156, Durham, NC 27710, USA
    Biochem Biophys Res Commun 398:585-7. 2010
    ..Studies on the cell-lineages of tumors with IDH1/2 mutations may help clarify the role of these mutations in the development of brain tumors...
  83. ncbi request reprint Second messenger systems in human gliomas
    Roger E McLendon
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Arch Pathol Lab Med 131:1585-90. 2007
    ....
  84. ncbi request reprint Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme
    David A Reardon
    Department of Medicine, Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA
    J Clin Oncol 23:9359-68. 2005
    ....
  85. ncbi request reprint Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma
    David A Reardon
    AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Clin Cancer Res 12:860-8. 2006
    ....
  86. ncbi request reprint Correlation of 1p-19q-defects in human gliomas with the light microscopic appearance of oligodendroglioma
    Roger E McLendon
    Mod Pathol 17:604-5. 2004
  87. ncbi request reprint A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group
    Murali M Chintagumpala
    Baylor College of Medicine, 6621 Fannin, CC 1510 00, Houston, TX, USA
    J Neurooncol 77:193-8. 2006
    ..Future trials should consider strategies to overcome the resistance mechanisms in children with high-grade glioma...
  88. ncbi request reprint MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy
    Kalman Kovacs
    Acta Neuropathol 115:261-2. 2008
  89. ncbi request reprint Recurrent glioblastoma diagnosed by fluorescence in situ hybridization for EGFR
    M Natalie Grunkemeier
    Acta Neuropathol 113:217-9. 2007
  90. ncbi request reprint Is the long-term survival of patients with intracranial glioblastoma multiforme overstated?
    Roger E McLendon
    Department of Pathology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer 98:1745-8. 2003
    ..The authors hypothesized, based on the literature, that even this remarkably poor survival rate is an overstatement. They investigated this hypothesis using the the Duke University Medical Center Tumor Registry...
  91. ncbi request reprint Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma
    Lars M Wagner
    Division of Pediatric Hematology Oncology, Cincinnati Children s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229, USA
    Clin Cancer Res 13:5418-25. 2007
    ..We hypothesized that the DNA repair protein methylguanine-DNA methyltransferase (MGMT) is an important resistance factor, and that inactivation of MGMT would sensitize neuroblastoma cells to these agents...
  92. ncbi request reprint Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium
    Nancy D Doolittle
    Department of Neurology, Oregon Health and Science University, 3181 SW Sam Jackson Park Road L603, Portland, OR 97201 3098, USA
    Clin Cancer Res 8:1702-9. 2002
    ....
  93. doi request reprint Protocol for the examination of specimens from patients with tumors of the brain/spinal cord
    Joseph E Parisi
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Arch Pathol Lab Med 132:907-12. 2008
  94. ncbi request reprint Cerebellopontine angle craniopharyngioma: case report and literature review
    Ciaran J Powers
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
    Pediatr Neurosurg 43:158-63. 2007
    ..This is only the third published report of craniopharyngioma occurring in isolation in the cerebellopontine angle. The case report and a brief review of the literature are presented...
  95. pmc Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft
    Naji Aldosari
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Neuro Oncol 4:75-85. 2002
    ....
  96. ncbi request reprint Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression
    David H George
    Department of Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Surg Pathol 27:487-93. 2003
    ..Central nervous system ALCL is aggressive. Our study suggests that a better outcome may be associated with young age and ALK-1 positivity, prognostic parameters similar to systemic ALCL...
  97. ncbi request reprint Accreditation council for graduate medical education (ACGME) competencies in neuropathology training
    Barbara J Crain
    Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    J Neuropathol Exp Neurol 64:273-9. 2005
    ..Many of the suggested activities and documentation methods can be combined into efficient, carefully formulated training/evaluation exercises. Different tools may be more applicable in some training programs...
  98. doi request reprint Issues of diagnostic review in brain tumor studies: from the Brain Tumor Epidemiology Consortium
    Faith G Davis
    Division of Epidemiology Biostatistics, School of Public Health, University of Illinois at Chicago, Chicago, IL 60612, USA
    Cancer Epidemiol Biomarkers Prev 17:484-9. 2008
    ..It is essential that epidemiologists and neuropathologists collaborate to develop appropriate study designs and protocols for specific hypothesis and populations...
  99. doi request reprint Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition
    Daniel J Brat
    Department of Pathology, EmoryUniversity, Atlanta, GA, USA
    Arch Pathol Lab Med 132:993-1007. 2008
    ..A number of established brain tumors are reorganized, including medulloblastomas and primitive neuroectodermal tumors, in an attempt to more closely align classification with current understanding of central nervous system neoplasia...
  100. ncbi request reprint Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma
    Amy B Heimberger
    Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
    Neurosurgery 50:158-64; discussion 164-6. 2002
    ..The purpose of this study was to demonstrate that DC-based immunizations directed solely against this tumor-specific antigen, which is commonly found on tumors that originate within or metastasize to the brain, could be efficacious...